Emese Zsiros, MD, PhD
Zoptarelin doxorubicin (Zoptrex), a hybrid molecule combining an LHRH-agonist and doxorubicin, failed to improve median overall survival (OS) in a phase III advanced endometrial cancer trial, according to the manufacturer of the treatment, Aeterna Zentaris.
The FDA rejected macimorelin in 2014, saying that Aeterna Zentaris would have to conduct a new trial to demonstrate efficacy.
Emons G, Grigor G, Harter P, et al. Efficacy and safety of AEZS-108 (LHRH agonist linked to doxorubicin) in women with advanced or recurrent endometrial cancer expressing LHRH receptors: a multicenter phase 2 trial (AGO-GYN5). Int J Gynecol Cancer. 2014;24:260-265.
... to read the full story